Saridegib is primarily used in the field of oncology as a hedgehog pathway inhibitor. It is being investigated for its potential to treat various types of cancers, particularly basal cell carcinoma and medulloblastoma. By targeting the hedgehog signaling pathway, which is often abnormally activated in these cancers, Saridegib aims to inhibit tumor growth and progression. Clinical trials are ongoing to evaluate its efficacy and safety in patients, with the hope of providing a new therapeutic option for those with limited treatment alternatives. Additionally, research is exploring its use in combination with other anticancer agents to enhance overall treatment outcomes.